According to the company, in the Phase 3 RASolute 302 trial, daraxonrasib showed a roughly 60 per cent reduction in the risk of death and a doubling of median overall survival compared with standard second-line chemotherapy. …
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep 23
July 10, 2026 - - Podcast -
Disruption is the overdue remedy and how this debate can revitalise the PBS
July 10, 2026 - - Latest News -
Melbourne study links higher tumour radiation dose to longer progression-free survival
July 10, 2026 - - Latest News -
Older Australians are underestimating their personal risk from RSV
July 10, 2026 - - Latest News -
Territory partnership backs digital health push for diabetes, kidney and heart care
July 9, 2026 - - Latest News -
It might make sense to follow the process, mostly, but no need to keep patients waiting
July 9, 2026 - - Latest News -
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News